Roche Veteran Launches Biotech Aiming To Disrupt Eye Drug Market

EyeBio Raises $65m In Series A

 
• By Andrew McConaghie

Two veterans of the ophthalmology field are reuniting to launch a portfolio-based biotech company EyeBio.

Retinography
Alamy • Source: An aging population means demand for retinal disease therapies will continue to climb.

More from Business

More from Scrip